Vielh P, Spano J-P, Grenier J, Le Chevalier T, Soria J-C
Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France.
Crit Rev Oncol Hematol. 2005 Mar;53(3):193-7. doi: 10.1016/j.critrevonc.2004.10.007.
Lung cancer retains the leading position in cancer-related deaths in the western countries. Non-small cell lung cancer (NSCLC) comprises more than 80% of lung cancers, and complete surgical resection of primary tumors in early-stage disease is the only potentially curative treatment. One area of intense research on early-stage NSCLC is the identification of molecular markers to complement TNM staging to fully assess the prognosis of patients and to define innovative strategies. Numerous prognostic factors have been identified in patients with early-stage NSCLC that might enable classification of such patients into different subsets corresponding to different risks of recurrence following complete resection. Most of the markers are proteins that can be detected by immunohistochemistry assays based on the antigen-antibody reaction. The present review aims at providing a panorama on classical as well as new prognostic markers. Of special interest are some molecular factors, already or currently tested from a prognostic point of view, that might also become good candidates for predicting treatment efficacy.
在西方国家，肺癌在癌症相关死亡中仍占据首位。非小细胞肺癌（NSCLC）占肺癌的80%以上，早期疾病的原发性肿瘤完整手术切除是唯一可能治愈的治疗方法。早期NSCLC的一个热门研究领域是识别分子标志物，以补充TNM分期，从而全面评估患者预后并确定创新策略。在早期NSCLC患者中已鉴定出众多预后因素，这些因素可能有助于将此类患者分为不同亚组，对应完全切除后不同的复发风险。大多数标志物是蛋白质，可通过基于抗原-抗体反应的免疫组织化学检测来检测。本综述旨在全景介绍经典及新的预后标志物。特别值得关注的是一些已从预后角度进行过测试或目前正在测试的分子因素，它们也可能成为预测治疗效果的良好候选因素。
